Skip to content
Review Open access

Autologous haematopoietic stem cell transplantation in patients with multiple sclerosis: Experience from South Africa

Oct 2026 · South African Medical Journal · 0 citations · 25 references

TL;DR

ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA and its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs.

Abstract

Background. Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disease that remains a major cause of neurological disability in young adults. While disease-modifying therapies (DMTs) can delay progression, many patients with highly active relapsing- remitting MS (RRMS) continue to experience breakthrough disease. Autologous haematopoietic stem cell transplantation (ASCT) offers durable immune reconstitution and remission but remains underutilised in upper-middle-income settings such as South Africa (SA). Objective. To evaluate the safety, feasibility and clinical outcomes of ASCT for MS in a real-world SA cohort. Methods. We conducted a retrospective record review of all MS patients who underwent ASCT between 1 January 2009 and 31 December 2024 at two JACIE-accredited tertiary centres (Wits Donald Gordon Medical Centre and Netcare Pretoria East Hospital). Data were extracted from institutional transplant records and analysed using descriptive statistics and Kaplan-Meier survival estimates. The primary outcome was the safety of ASCT for MS, and the secondary outcomes were the clinical outcomes of patients who underwent ASCT for MS. Results. Thirty-two patients were included (median age 42 years; 53% female; 94% RRMS). Median disease duration prior to ASCT was 7.4 years, and 97% had received prior DMTs. Conditioning included cyclophosphamide (97%), anti-thymocyte globulin (69%) and fludarabine (34%). The median neutrophil and platelet engraftment occurred at 10 and 14 days, respectively. Relapse-free survival was 100% at 1 year and 91% (95% confidence interval 68 - 98) at 5 years. Approximately 90% of evaluable patients demonstrated neurological improvement or stabilisation at 1 year. Treatment-related adverse events occurred in 63% of cases, and 95% of these side-effects were grade 3 or less: most commonly neutropenic fever (50%) and mucositis (16%). Only 5% of adverse reactions were grade 4, with no transplant-related mortality. Conclusion. ASCT is safe, feasible and highly effective in aggressive, treatment-refractory RRMS in SA. Its earlier use in selected patients may offer durable remission and substantial cost savings compared with long-term DMTs. The expansion of accredited national ASCT programmes and registry-based outcome monitoring is warranted.    

Read PDF

Similar papers

Open access Oct 2026

Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study.

Long-term follow-up data after autologous HSCT in patients with systemic sclerosis is provided allowing robust assessment of response rate, late complications, and sustained treatment benefit, and might serve as an important comparator for all upcoming, cellular treatment options.

J. Henes, M. Oliveira, M. Labopin et al. · 1 citation
Open access Oct 2026

Incidence and characteristics of cytokine release syndrome in patients with systemic sclerosis undergoing autologous haematopoietic stem cell transplantation.

BACKGROUND Systemic sclerosis (SSc) is a debilitating autoimmune connective tissue disease associated with high morbidity and mortality. Autologous hematopoietic stem cell transplantation (HSCT) improves survival in diffuse cutaneous SSc. Cytokine release syndrome (CRS), a potentially fatal inflammatory response, is a...

Charlotte S. Schimmel, E. Hoekstra, M. Koops et al. · 0 citations
Open access Oct 2026

Outcome of allogenic bone marrow transplantation in aplastic Anaemia

Allogeneic bone marrow transplantation was found to be a viable curative treatment for severe aplastic anaemia even in resource-limited settings.

Shehzad Sarwar, Uzair Ahmed, Hafiz Muhammad Nadeem et al. · 0 citations
Open access Oct 2026

Second allogeneic haematopoietic stem cell transplantation for non-malignant diseases.

We retrospectively analysed clinical outcomes of 152 patients with non-malignant diseases (NMDs) who underwent a second allogeneic haematopoietic stem cell transplantation (HSCT), using a composite end-point, graft-versus-host disease (GVHD)-free, relapse (i.e. graft failure)-free and subsequent transplant-free surviva...

Maiko Shimomura, Koji Kawaguchi, Shohei Yamamoto et al. · 0 citations
Sep 2026

Allogeneic haematopoietic stem cell transplantation in late-onset metachromatic leukodystrophy.

Comparing the long-term outcomes of the largest European cohort of HSCT-treated and untreated late-juvenile and adult MLD patients provides an evidence base for future comparison with innovative therapies and underscores the importance of early diagnosis and intervention.

D. Schoenmakers, M. Datema, Shanice Beerepoot et al. · 0 citations
Open access Oct 2026

Hematopoietic Cell Transplantation in Children with Sickle Cell Disease: A Single-Center Experience and Exploration of an Age Threshold for Post-Transplant Complications

Background/Objectives: Hematopoietic cell transplantation (HCT) is the only established curative option for sickle cell disease (SCD), yet the optimal timing in pediatric cohorts remains incompletely defined. Methods: We retrospectively analyzed all patients under 20 years with SCD who underwent HCT at the University H...

C. Nazon, Chloé Gerber, Alexandra Salmon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.